4th In Vivo Cell Engineering and Gene Editing Summit

Welcome to the 4th In Vivo Cell Engineering and Gene Editing Summit, the premier event dedicated to enhancing the next frontier of in vivo cell and gene approaches from research to clinic. This summit provides you with exclusive insights into the latest IND enabling data, regulatory and inter-governmental processes and requirements, best-in-class delivery technologies, cutting-edge innovations in editing and engineering and insights into effective clinical trial design from industry leaders including Capstan Therapeutics, Editas Medicine, Carisma Therapeutics, AbbVie, Intellia Therapeutics, Umoja Biopharma and many more!

The in vivo approach is revolutionizing the cell and gene space. These ground-breaking technologies promise more efficient, accessible and cost-effective therapies and paving the way for the future of cell and gene treatments. With leading companies entering the clinic and investments and collaborations unfolding, the potential of in vivo therapies to treat a variety of indications including oncology, genetic and rare diseases is now front and centre.

Gain exclusive access to ground-breaking discoveries and networking opportunities to propel your pipelines to new heights!

URLs:
Brochure: https://go.evvnt.com/2884100-0?pid=185
Tickets: https://go.evvnt.com/2884100-1?pid=185

Time: 8:00 AM - 5:00 PM

Speakers: Cecile Bauche, Founder and Chief Scientific Officer, Alaya.bio, Adrian Bot, Founding Chief Scientific Officer and Executive Vice President - Research and Development, Capstan Therapeutics, Delai Chen, Director - Nanoparticle Formulation, Beam Therapeutics Inc., Gilmore O'Neill, President and Chief Executive Officer, Editas Medicine, Michael Klichinsky, Co-Founder and Chief Scientific Officer, Carisma Therapeutics, Laura Green Director, Program Management, Umoja Biopharma, Daniel Getts, Chief Executive Officer, Myeloid Therapeutics, Robert Hofmeister, Chief Scientific Officer, Myeloid Therapeutics